1/12
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai |
|---|
No analytics yet
Send a link to your students to track their progress
APL with PML::RARA fusion
Long-term cure rates >90%
AML with RUNX1::RUNX1T1 fusion
High rates of complete remission and disease-free survival
AML with CBFB::MYH11 fusion
Favorable prognosis
AML with DEK::NUP214 fusion
Poor prognosis
AML with RBM15::MRTFA fusion
No uniform prognosis
AML with BCR::ABL1 fusion
Poor response to standard induction chemotherapy
AML with KMT2A rearrangement
Prognosis depends on fusion partner
AML with MECOM rearrangement
Aggressive disease with short survival
AML with NUP98 rearrangement
Poor prognosis
AML with NPM1 mutation
Typically shows good response to standard chemotherapy
AML with CEBPA mutation
Variable prognosis depending on CEBPA mutation type
AML, myelodysplasia-related
Poor prognosis
AML with other defined genetic alterations
Prognosis based on specific alteration